A New England Journal of Medicine analysis outlines critical practical considerations for healthcare providers navigating emerging state psychedelic therapy regulations. Key findings indicate that specialized training exceeding 100 hours is required for providers, with rigorous safety protocols essential for clinical implementation in controlled therapeutic environments.
States are implementing highly variable regulatory approaches—some focusing exclusively on psilocybin for treatment-resistant depression while others include MDMA for PTSD treatment. Providers must understand their specific state’s regulatory framework, as state-federal compliance tensions create complex licensing and practice requirements.
The analysis emphasizes that state innovation is driving mental health treatment evolution, but healthcare systems must maintain rigorous safety standards, ensure appropriate provider credentialing, and stay informed about changing regulations. Understanding these state-level frameworks is essential for clinicians seeking to participate in psychedelic-assisted therapy programs.
Was this article helpful?
